Febrile Neutropenia Prophylaxis in Cancer Patients
📧 Sign up to get email alerts when something new happens for Febrile Neutropenia Prophylaxis in Cancer Patients.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-14EMA Authorised: Fulphila (pegfilgrastim) — Biosimilar Collaborations Ireland Limited
The EMA authorises Fulphila (pegfilgrastim) as a biosimilar, granting marketing authorization to Biosimilar Collaborations Ireland Limited.